Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS

Summary

The purpose of this study is to find a new way to treat Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML). All the drugs are used to treat AML and MDS but are not usually combined together. The investigators are looking at both the safety and Efficacy of each combination.

Timeline

Start

2013-04-01

Primary completion

2018-06-26

Completion

2020-04-16

Outcome

Met primary endpoint

paper Response rates were 26.7% for DAC alone, 14.3% for DAC/Carbo, and 32.3% for DAC/ATO, with DAC/ATO achieving significantly higher responses (P = .041) PMID 40453133 ↗

Publications

• Kropf PL, Chung W, Shameem R, Xiao L, Balch C, Huang X, Issa JJ. A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML. Blood Neoplasia. 2025 Jan 23;2(2):100071. doi: 10.1016/j.bneo.2025.100071. eCollection 2025 May.

Drugs

Indications